Sibutramine: a novel new agent for obesity treatment (Q41026257)

25 September 2017

1 reference

title

Sibutramine: a novel new agent for obesity treatment (English)

1 reference

25 September 2017

0 references

1 reference

3

Bray GA

1 reference

25 September 2017

Ryan DH

1

1 reference

PubMed ID

8697058

25 September 2017

Kaiser P

series ordinal

2

1 reference

25 September 2017

1 November 1995

1 reference

25 September 2017

1 reference

25 September 2017

3 Suppl 4

1 reference

25 September 2017

553S-559S

1 reference

Barriers to the Treatment of Obesity

25 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1550-8528.1995.TB00227.X

Use and abuse of appetite-suppressant drugs in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1550-8528.1995.TB00227.X

The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1550-8528.1995.TB00227.X

Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1550-8528.1995.TB00227.X

Sibutramine in weight control: a dose-ranging, efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1550-8528.1995.TB00227.X

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1550-8528.1995.TB00227.X

10.1002/J.1550-8528.1995.TB00227.X

21 January 2018

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8697058